Table 1.
Nr. of patients | CT | MRI | CT and/or MRI | [18F]-FDA | [123I]-MIBG | [131I]-MIBG | [123I] or [131I]-MIBG | |
---|---|---|---|---|---|---|---|---|
Non-metastatic | ||||||||
PHEO | 26 | 26 (100%) | 20 (77%) | 26 (100%) | 26 (100%) | 21 (81%) | 2 (8%) | 23 (88%) |
Metastatic PHEO | 34 | 32 (94%) | 31 (91%) | 34 (100%) | 34 (100%) | 21 (62%) | 10 (29%) | 31 (91%) |
PHEO total | 60 | 58 (97%) | 51 (85%) | 60 (100%) | 60 (100%) | 42 (70%) | 12 (20%) | 54 (90%) |
No PHEO | 39 | 29 (74%) | 25 (64%) | 31 (79%) | 39 (100%) | 21 (54%) | 2 (5%) | 23 (59%) |
Total | 99 | 87 (88%) | 76 (77%) | 91 (92%) | 99 (100%) | 63 (64%) | 14 (14%) | 77 (78%) |